Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Clinical trial NCT04739813 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04739813
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-09
- Primary completion
- 2026-05-07
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.